Przejdź do zawartości
Merck

937266

Sigma-Aldrich

NanoFabTx for gene delivery

Maleimide lipid mix

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Kod UNSPSC:
12352142
NACRES:
NA.21

Poziom jakości

Zastosowanie

advanced drug delivery

temp. przechowywania

−20°C

Opis ogólny

Maleimide lipid mix for gene delivery and targeted delivery
The NanoFabTx gene delivery maleimide lipid mix is a ready-to-use nanoformulation lipid mixture for the synthesis of maleimide-functionalized lipid nanoparticles (LNPs).These lipid nanoparticles can be used for targeting and immunotherapy applications, and nucleic acid encapsulation.

This product is a curated lyophilized lipid mixture of rationally selected lipids in precise ratios that have been optimized to achieve a desired size range of lipid nanoparticles. Step-by-step protocols for the synthesis of maleimide-functionalized LNPs by microfluidics with the NanoFabTx microfluidic- nano device kit (Cat. No. 911593) or nanoprecipitiation are included.

Maleimide-functionalized LNPs are particularly advantageous for gene delivery because the maleimide functional group enables the conjugation of thiol-containing antibodies, proteins, aptamers, or other molecules to the lipid nanoparticle surface. This can be used for multi-targeting or multi-type cargo delivery to different cell types including immune cells, making it advantageous for many different therapuetic applications including mRNA vaccine delivery and oncology.

Zastosowanie

With the NanoFabTx gene delivery maleimide lipid mix, researchers can simplify their drug development workflow. The ready to use mix enables the screening of different drug modalities such as oligonucleotides, nucleic acids (mRNA, DNA, siRNA), and vaccines without the need to develop new drug delivery formulations from scratch, ultimately speeding up the time it takes for innovative therapeutics to go from the bench to the clinic. The maleimide-functionalized surface of the LNP can be used to conjugate to many different thiol-containing biomolecules for active targeting. This ready-to-use lipid mix can also be used to screen different targeting moieties to determine what works best for your therapuetic and application. In addition, the lipid mix has been carefully crafted for enhanced gene delivery.

Cechy i korzyści

  • A ready-to-use nanoformulation lipid blend to synthesize Maleimide-functionalized lipid nanoparticles
  • Step-by-step protocols developed and tested by our formulation scientists
  • Flexible synthesis tool to create uniform and reproducible lipid nanoparticles
  • Optimized to make lipid nanoparticles around 100 nm with low polydispersity
  • Optimized lipid blend for thiol-containing protein or antibody conjugation
  • Optimized lipid blend for Maleimide-functionalized lipid nanoparticles for mRNA encapsulation
For more information, please refer to the protocol under the document section of this page.

Informacje prawne

Legal Information NanoFabTx is a trademark of Sigma-Aldrich Co. LLC
NANOFABTX is a trademark of Sigma-Aldrich Co. LLC
This page may contain text that has been machine translated.

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 3


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Targeted delivery of lipid nanoparticle to lymphatic endothelial cells via anti-podoplanin antibody
Sakurai Y, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society, 349, 379-387 (2022)
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
Tombacz I, et.al.
Molecular Therapy, 29(11), 3293-3304 (2021)
István Tombácz et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 29(11), 3293-3304 (2021-06-07)
Nucleoside-modified messenger RNA (mRNA)-lipid nanoparticles (LNPs) are the basis for the first two EUA (Emergency Use Authorization) COVID-19 vaccines. The use of nucleoside-modified mRNA as a pharmacological agent opens immense opportunities for therapeutic, prophylactic and diagnostic molecular interventions. In particular
Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics
Dammes N, et al.
Nature Nanotechnology, 16(9), 1030-1038 (2021)
In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles
Fang-Yi S, et al.
Science advances, 8(8), eabm7950- eabm7950 (2022)

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej